The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Hologic (NASDAQ:HOLX) and its peers.
Hologic declined a $16 billion buyout bid from TPG and Blackstone as it faces falling shares and tariff-related headwinds, leaving room for deal talks to potentially resume.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Shares of medical technology company Hologic (NASDAQ:HOLX) jumped 18.6% in the afternoon session after the Financial Times reported that private equity firms TPG and Blackstone made an offer to buy the company (HOLX).
Wall Street charged higher Tuesday, with U.S. equities posting broad-based gains by midday as investors embraced a risk-on mood, spurred by easing Treasury yields and renewed optimism surrounding trade talks between the U.S. and the European Union.
Shareholders of Hologic would probably like to forget the past six months even happened. The stock dropped 28.3% and now trades at $56.47. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
Medical technology company Hologic (NASDAQ:HOLX) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.2% year on year to $1.01 billion. The company expects next quarter’s revenue to be around $1.01 billion, close to analysts’ estimates. Its non-GAAP profit of $1.03 per share was 1.4% above analysts’ consensus estimates.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
will be announcing earnings results tomorrow before market open. Here’s what you need to know.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Medical technology company Hologic (NASDAQ:HOLX) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.2% year on year to $1.01 billion. On the other hand, next quarter’s revenue guidance of $1.01 billion was less impressive, coming in 2% below analysts’ estimates. Its non-GAAP profit of $1.03 per share was 1.4% above analysts’ consensus estimates.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - imaging, diagnostics stocks fared in Q4, starting with Hologic (NASDAQ:HOLX).
Wall Street pushed higher in midday trading, with the S&P 500 on track for its eighth consecutive gain — its longest winning streak since November 2023. The index rose about 1% to 5,560, fully recovering the losses sustained after former President Donald Trump announced trade tariffs on April 2.
